CREBBP and MALT lymphoma: This suggests that epigenetic modulation of immune response with HDAC3 inhibitors (or EZH2 inhibitors) may be explored in CREBBP-mutant MALT lymphomas, alone or in combination with PD1/PD-L1 blockade (to prevent interferon-induced adaptive immune suppression).